Pliant Therapeutics Enters into $100 million Loan Facility Agreement with Oxford Finance to Support Ongoing Development of PLN-74809

Voyager Therapeutics Reports First Quarter 2022 Financial and Operating Results

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Idiopathic Pulmonary Fibrosis

insitro Announces Formation of Scientific Advisory Board to Support Platform and Pipeline Advancement

Abata Therapeutics Appoints Sandy Lazzari as Chief People Officer